• About us
  • Team
  • Privacy Policy
  • Contact
Thursday, October 15, 2026
  • Login
No Result
View All Result
World's first weekly chronicle of development news
  • Blitz Highlights
    • Special
    • Spotlight
    • Insight
    • Entertainment
    • Sports
  • Opinion
  • Legal
  • Perspective
  • Nation
    • East
    • West
    • North
    • South
  • Business & Economy
  • World
  • Hindi Edition
  • International Editions
    • Dubai
    • Tanzania
    • United Kingdom
    • USA
  • Blitz India Business
  • Blitz Highlights
    • Special
    • Spotlight
    • Insight
    • Entertainment
    • Sports
  • Opinion
  • Legal
  • Perspective
  • Nation
    • East
    • West
    • North
    • South
  • Business & Economy
  • World
  • Hindi Edition
  • International Editions
    • Dubai
    • Tanzania
    • United Kingdom
    • USA
  • Blitz India Business
No Result
View All Result
World's first weekly chronicle of development news
No Result
View All Result

Concerns over vaccine policy

Twelve former FDA chiefs question regulation changes

by Blitz India Media
December 8, 2025
in USA
0
Concerns over vaccine policy
Blitz Bureau

NEW DELHI: Twelve former U.S. FDA commissioners said on December 3 that they were deeply concerned about proposed changes to vaccine regulation by the agency’s chief scientific officer and the details of his assertion that the COVID-19 vaccine killed 10 children. The commissioners were responding to an email sent last week by Vinay Prasad, the Food and Drug Administration’s chief medical and scientific officer, in which he told agency staffers that COVID-19 vaccinations probably contributed to the deaths of at least 10 children who died of heart inflammation, but provided few details on how the analysis of those cases was performed. Prasad also outlined planned changes to regulation of vaccines, including annual flu shots, saying that companies must prove that vaccines work through randomized trials rather than ones that demonstrate the shots elicit an immune response.

“The proposed guidelines would dramatically change vaccine regulation on the basis of a reinterpretation of selective evidence and by a process that breaks sharply with the norms that have anchored the FDA’s globally respected scientific integrity,” the former FDA commissioners, who served under both Republican and Democratic presidents, wrote in a piece published in the New England Journal of Medicine, according to a Reuters report. The authors include Scott Gottlieb and Brett Giroir, who served as commissioners during President Donald Trump’s first term.

“The fact these criticisms are coming from former FDA officials who opposed raising the bar for vaccine science confirms we are on the right track,” HHS spokesperson Andrew Nixon said in an emailed statement.

Prasad’s memo, the commissioners wrote, “offered no explanation of the process and analyses that were used to reach the new retrospective judgment, nor did it indicate why that assessment should justify wholesale rewriting of vaccine regulation.” Prasad was hired by Health Secretary Robert F. Kennedy Jr., a long-time anti-vaccine activist, who has been working to remake U.S. vaccine policy and has called for placebo-based trials of vaccines in the past. Many scientists say it is not typically possible to run such trials for ethical reasons.

Related Posts

Migrant Deportation
USA

SC nod for deportations

October 5, 2026
Mamdani’s moment
USA

Mamdani’s moment

October 5, 2026
white-house
USA

Senate backs Trump

October 5, 2026
A fillip for save system
USA

A fillip for save system

October 5, 2026
US President Donald Trump
USA

Trump’s NEW ULTIMATUM

September 21, 2026
Trump Census 2030 immigration changes
USA

Changes in census coming

September 21, 2026
Load More
Next Post
‘Repeal Pak blasphemy law’

‘Repeal Pak blasphemy law’

Recent News

Third road to Ladakh opens new strategic route
News

Third road to Ladakh opens new strategic route

by Blitz India Media
October 15, 2026
0

LEH, 15 October For most of the year, Ladakh depended on two roads to connect from rest of India, the...

Read moreDetails
Rajnath Singh

India offers ASEAN joint manufacture of defence systems

October 14, 2026
India Canada diplomatic ties

India News: Canada Ties, Ports, Minerals and Stubble Fires

October 14, 2026
Asian Champions Trophy 2026

Pathak returns as India names squad for Asian Champions Trophy

October 13, 2026
Electronics production grows seven-fold : MeitY

New Delhi, 13 October : India’s fintech sector raised $2.2 billion in the first nine months of 2026 (January 1, 2026–September 30, 2026), up 14 per cent from $1.9 billion in the same period a year earlier, a report said. The report from data intelligence platform Tracxn Technologies Limited said funding rounds dipped from 260 to 153, adding that the funding was concentrated in a smaller number of large late‑stage rounds, with five mega‑rounds of $100 million or more accounting for $1.1 billion or 48 per cent of total capital. The report said in the first nine months of 2026, digital lending and payments topped the category rankings, while Bengaluru accounts for over three-fifths of all capital raised. On the exit side, IPOs saw a 50 per cent uptick while overall acquisitions slowed. As many as 30 companies raised their first funding round, down 49 per cent from 59 in the previous year. Series A and later rounds totalled 77, down 31 per cent from 112. Late-stage funding (Series C+, PE, and pre-IPO) led the mix, rising 95 per cent to $1.5 billion in the first nine months of 2026 — up from $751 million during the same period in the previous year. This capital surge pushed late-stage investments to 67 per cent of total market funding, the report noted. Earlier stages experienced contractions in capital and deal counts. Early-stage funding fell 33 per cent to $668 million across 52 rounds, compared to $1 billion across 82 rounds in nine months of 2025. Seed funding fell 57 per cent to $73.8 million across 76 rounds, down from $173 million across 148 rounds. New unicorns crossed the billion-dollar threshold in an average of 7.1 years after their Series A funding. Moreover, the industry saw 3 IPOs in nine months of 2026, up 50 per cent from 2 in the previous year, alongside 11 acquisitions, down 45 per cent from 20.

October 13, 2026

Blitz Highlights

  • Special
  • Spotlight
  • Insight
  • Entertainment
  • Health

International Editions

  • US (New York)
  • UK (London)
  • Middle East (Dubai)
  • Tanzania (Africa)

Nation

  • East
  • West
  • South
  • North
  • Hindi Edition

E-paper

  • India
  • Hindi E-paper
  • Dubai E-Paper
  • USA E-Paper
  • UK-Epaper
  • Tanzania E-paper

Useful Links

  • About us
  • Team
  • Privacy Policy
  • Contact

©2024 Blitz India Media -Building A New Nation

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In

    No Result
    View All Result
    • Blitz Highlights
      • Special
      • Spotlight
      • Insight
      • Entertainment
      • Sports
    • Opinion
    • Legal
    • Perspective
    • Nation
      • East
      • West
      • North
      • South
    • Business & Economy
    • World
    • Hindi Edition
    • International Editions
      • Dubai
      • Tanzania
      • United Kingdom
      • USA
    • Blitz India Business

    ©2024 Blitz India Media -Building A New Nation